UK markets closed

Molecular Partners AG (0QXX.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
8.92-0.32 (-3.46%)
At close: 02:42PM BST
Full screen
Previous close9.24
Bid0.00 x 0
Ask0.00 x 0
Day's range8.79 - 9.20
52-week range3.04 - 9.20
Avg. volume6,578
Market cap159.81M
Beta (5Y monthly)0.78
PE ratio (TTM)0.03
EPS (TTM)3.31
Earnings date26 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announce that the Company will present in a fireside chat at the 2nd TD Cowen Radiopharmaceutical Innovation Summit today, June 17, 2024 at 10:40 a.m. ET (4:40 p.m. CET). Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Execut

  • GlobeNewswire

    Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

    Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effectsMP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua

  • GlobeNewswire

    Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

    MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profileFirst-in-human study in planning with initial data expected in 2025RDT platform expanding with portfolio of additional targets under evaluation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement